Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A rationally designed oral vaccine should be successfully delivered to the intestinal mucosal immune cells, and induce both humoral and cellular counterparts of immunity along with the mucosal immune response. The aim of this study is to mimic these natural infections and excel the utility of a specific ligand for beta1 integrin (RGD peptide) to target M cells which seems to be the only portal for any particulate matter in GIT. The in vivo studies have shown higher antibody titre for alginate coated chitosan nanoparticles compared to plain chitosan nanoparticles. RGD peptide conjugated alginate coated chitosan nanoparticles proved to be the suitable carrier system for antigen delivery to gut associated lymphoid tissue. Based upon the release kinetics and strong systemic as well as mucosal immune response we can conclude that this cost effective carrier construct can be utilized for oral vaccination.

Download full-text PDF

Source
http://dx.doi.org/10.1166/jbn.2011.1236DOI Listing

Publication Analysis

Top Keywords

mucosal immune
12
chitosan nanoparticles
12
immune response
8
rgd peptide
8
alginate coated
8
coated chitosan
8
surface engineered
4
nanoparticles
4
engineered nanoparticles
4
nanoparticles oral
4

Similar Publications

Vitamin D has been proposed to attenuate chemotherapy-induced gastrointestinal mucositis (GM). In the intestine, local catabolism of active vitamin D [1,25-dihydroxyvitamin D₃] is mediated by the enzyme Cyp24a1. This study assessed whether deletion of Cyp24a1 specifically in intestinal epithelial cells can protect against 5-fluorouracil (5-FU)-induced intestinal injury and microbiome disruption in mice.

View Article and Find Full Text PDF

Optimizing mucosal vaccination: Exploiting Lactobionic acid-modified chitosan for superior gene delivery systems.

Int J Biol Macromol

September 2025

CNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-504, Portugal; CIBB - Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, 3004-504, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, 3000-548, Portugal. Electronic a

The increasing prevalence of respiratory disorders highlights the urgent need for effective mucosal vaccines that elicit targeted immune responses at pathogen entry sites. However, the advancement of mucosal vaccines is limited by challenges in antigen delivery and overcoming mucosal immune tolerance. In this study, we developed a gene delivery platform using chitosan functionalized with lactobionic acid (LA) to enhance targeting of antigen-presenting cells and to form stable DNA polyplexes with high transfection efficiency.

View Article and Find Full Text PDF

Innovative engineering approaches to model host-microbiome interactions in vitro.

Adv Drug Deliv Rev

September 2025

J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States. Electronic address:

The human microbiome plays a critical role in health and disease. Disruptions in microbiota composition or function have been implicated not only as markers but also as drivers of diverse pathologies, creating opportunities for targeted microbiome interventions. Advancing these therapies requires experimental models that can unravel the complex, bidirectional interactions between human tissue and microbial communities.

View Article and Find Full Text PDF

Ethnopharmacological Relevance: Shen Ling Bai Zhu San (SLBZS) is a classical Chinese herbal formula and has been used for treating chronic diarrhea (CD) for several centuries. However, there is a lack of robust evidence on how SLBZS regulates immune function to improve CD.

Aim Of The Study: To reveal the spleen-invigorating and antidiarrheal effects of SLBZS in chronic diarrhea mice induced by spleen-deficiency, as well as to explore the underlying mechanism.

View Article and Find Full Text PDF

Mycoplasma gallisepticum (MG) is one of the main pathogens causing chronic respiratory diseases in chickens, which seriously affects the sustainable and healthy development of the poultry industry and leading to heavy economic losses. Therefore, we developed a safe, efficient, convenient, and low-cost MG oral vaccine. The vaccine is based on a recombinant yeast surface display system to compensate for the shortcomings of existing vaccines.

View Article and Find Full Text PDF